ACET Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Adicet Bio Inc (ACET) is not a strong buy at the moment for a beginner investor with a long-term strategy. The stock shows no significant positive catalysts, weak financial performance, and lacks trading signals from proprietary tools. While analysts maintain a Buy rating, the recent reverse stock split and lack of growth in revenue or profitability make it a less compelling investment currently.
The MACD is positive and expanding, indicating a mild bullish trend. RSI is neutral at 57.113, and moving averages are converging, suggesting no clear trend. The stock is trading near its pivot level of 7.19, with resistance at 7.555 and support at 6.825. Overall, the technical indicators do not strongly support a buy decision.
Analysts maintain a Buy rating, and there is a potential for short-term price increases based on historical candlestick patterns.
The company recently underwent a reverse stock split to maintain NASDAQ listing requirements, which can indicate financial instability. No significant hedge fund or insider trading activity. Financials show no revenue growth and worsening net income and EPS.
In Q3 2025, the company reported no revenue growth (0% YoY), a net income drop of -11.88% YoY to -26.856 million, and an EPS decline of -12.10% YoY to -4.72. Gross margin remains at 0%.
H.C. Wainwright raised the price target to $50 from $9, citing the reverse stock split. Canaccord adjusted its target to $18 from $128, also reflecting the reverse split. Both firms maintain a Buy rating but acknowledge the stock's recent adjustments due to listing requirements.
